Research has shown that immunotherapy pembrolizumab alone and in combination with chemotherapy is a more efficacious first line treatment for head and neck cancer that has returned than aggressive chemotherapy.
4 June 2019
3 June 2019 News
AstraZeneca and Merck have announced that Lynparza (olaparib) demonstrated significant improvement in progression-free survival (PFS), compared to placebo, in germline BRCA-mutated metastatic adenocarcinoma of the pancreas.
30 May 2019 News
Combining Janssen’s Darzalex (daratumumab) with Celgene’s Revlimid (lenalidomide) and dexamethasone (Rd) increased progression-free survival (PFS) of newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplants.
30 May 2019 Comment
Prostate cancer screening guideline changes have significantly affected the epidemiology of prostate cancer in the US, resulting in a higher proportion of incident cases diagnosed at stage IV.
29 May 2019 News
Celgene has announced that the US Food and Drug Administration (FDA) has approved Revlimid (lenalidomide) in combination with rituximab (R2) for patients with previously treated follicular lymphoma (FL) and marginal...
28 May 2019 Comment
Over the next decade, GlobalData expects a large number of new mechanisms of action (MOAs) to enter the market.
28 May 2019 News
Novartis has announced the US Food and Drug Administration (FDA) has approved its drug Piqray (alpelisib) as the first PIK3CA inhibitor.
23 May 2019 Comment
The label expansion opens up yet another avenue of growth for BMS in addition to the five new brands expected to launch from the Celgene pipeline through 2020.
22 May 2019
Merck has signed a definitive agreement to acquire biopharmaceutical company Peloton Therapeutics for an upfront payment of $1.05bn.
20 May 2019 Comment
CAR-T therapies are among the highest priced drugs in the pharmaceutical market, and the price set in Japan is close to the $373,000 price set in the US.